[jeeshan]

Starting with mescaline, we are developing a portfolio of plant-identical psychedelic compounds for FDA approval through a stakeholder model that includes the community of clinicians, non-profits, and Indigenous groups whose work is foundational to the success of this sector.

[etr71115]

Where are you planning to go from there?

[jeeshan]

We're looking to meet with researchers and clinicians who want to develop other plant and natural medicines through a model that combines mission and the ability to scale.